OBJECTIVE There is mounting evidence regarding the cardiovascular benefits of sodium–
glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists …

Abstract The National Cardiovascular Data Registry PINNACLE (Practice Innovation and
Clinical Excellence) Registry is the largest outpatient cardiovascular practice registry in the …

Introduction: The emphasis on clinical trials to inform evidence-based medicine remains
paramount within the cardiovascular community. Although such high-quality evidence is …

Importance There is a paucity of data regarding secondary prevention care disparities in
women with premature and extremely premature atherosclerotic cardiovascular disease …

Background Multiple clinical trials have demonstrated significant cardiovascular benefit with
use of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with type 2 diabetes …

Importance Studies on the use of and adherence to secondary prevention therapies in
patients with premature and extremely premature atherosclerotic cardiovascular disease …

Background Although the association between autoimmune rheumatic diseases and
atherosclerotic cardiovascular disease is well-known, there is a lack of data regarding the …

The 2013 American College of Cardiology/American Heart Association cholesterol guideline
recommends moderate to high-intensity statin therapy in patients with peripheral artery …

Background: Patients with low-density lipoprotein cholesterol (LDL-C)≥ 190 mg/dL are at
high risk of atherosclerotic cardiovascular disease events. Treatment guidelines recommend …

Statins reduce cardiovascular disease (CVD) and mortality risk in patients with diabetes (1).
Practicelevel variation in statin use among diabetic patients in cardiology practices is …